Keith Humphreys

Executive

Director

Indivior Pharmaceuticals, Inc.Indivior PLC

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 1 buy · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (1 ops.)

€23k

▼ Sales (0 ops.)

—

Latest filing published 14 May 2026 for Indivior Pharmaceuticals, Inc..

Filing timeline

BuySale

Keith Humphreys

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Indivior PLC 1 purchase · last 07 Jan 2026

Keith Humphreys: trading record in brief

Keith Humphreys (senior executive) discloses dealings in 2 companies, chiefly Indivior Pharmaceuticals, Inc. and Indivior PLC. Between 5 January 2026 and 13 May 2026, the trades on record add up to 3 filings.

On the market, this insider has only ever bought: 1 purchase, €23k in total. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 2 share grants.

The latest filing, published on 14 May 2026, reports a share grant in Indivior Pharmaceuticals, Inc. The last insider purchase was made public on 7 January 2026, 290 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.